BIOMAT Database Logo BIOMAT Database Logo

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 1993

F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Division of Cardiology, Sahlgren's Hospital, Göteborg, Sweden.

Several small studies have suggested beneficial effects of long-term beta-blocker treatment in idiopathic dilated cardiomyopathy. Our large multicentre study aimed to find out whether metoprolol improves overall survival and morbidity in this disorder. 383 subjects with heart failure from idiopathic dilated cardiomyopathy (ejection fraction < 0.40) were randomly assigned placebo or metoprolol. 94% were in New York Heart Association functional classes II and III, and 80% were receiving background treatment. A test dose of metoprolol (5 mg twice daily) was given for 2-7 days; those tolerating this dose (96%) entered randomisation. Study medication was increased slowly from 10 mg to 100-150 mg daily. There were 34% (95% CI -6 to 62%, p = 0.058) fewer primary endpoints in the metoprolol than the placebo group; 2 and 19 patients, respectively, deteriorated to the point of needing transplantation and 23 and 19 died. The change in ejection fraction from baseline to 12 months was significantly greater with metoprolol than with placebo (0.13 vs 0.06, p < 0.0001). Pulmonary capillary wedge pressure decreased more from baseline to 12 months with metoprolol than with placebo (5 vs 2 mm Hg, p = 0.06). Exercise time at 12 months was significantly greater (p = 0.046) in metoprolol-treated than in placebo-treated patients. In patients with idiopathic dilated cardiomyopathy, treatment with metoprolol prevented clinical deterioration, improved symptoms and cardiac function, and was well tolerated.

UI MeSH Term Description Entries
D008297 Male Males
D008790 Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. Beloc-Duriles,Betaloc,Betaloc-Astra,Betalok,CGP-2175,H 93-26,Lopressor,Metoprolol CR-XL,Metoprolol Succinate,Metoprolol Tartrate,Seloken,Spesicor,Spesikor,Toprol,Toprol-XL,Beloc Duriles,Betaloc Astra,CGP 2175,CGP2175,H 93 26,H 9326,Metoprolol CR XL,Toprol XL
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010359 Patient Readmission Subsequent admissions of a patient to a hospital or other health care institution for treatment. Hospital Readmission,Rehospitalization,Unplanned Hospital Readmissions,Unplanned Readmission,30 Day Readmission,Hospital Readmissions,Readmission, Hospital,Readmissions, Hospital,Thirty Day Readmission,30 Day Readmissions,Hospital Readmission, Unplanned,Hospital Readmissions, Unplanned,Readmission, Patient,Readmission, Thirty Day,Readmission, Unplanned,Rehospitalizations,Thirty Day Readmissions,Unplanned Hospital Readmission,Unplanned Readmissions
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D002311 Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein. Cardiomyopathy, Congestive,Congestive Cardiomyopathy,Dilated Cardiomyopathy,Cardiomyopathy, Dilated, 1a,Cardiomyopathy, Dilated, Autosomal Recessive,Cardiomyopathy, Dilated, CMD1A,Cardiomyopathy, Dilated, LMNA,Cardiomyopathy, Dilated, With Conduction Defect 1,Cardiomyopathy, Dilated, with Conduction Deffect1,Cardiomyopathy, Familial Idiopathic,Cardiomyopathy, Idiopathic Dilated,Cardiomyopathies, Congestive,Cardiomyopathies, Dilated,Cardiomyopathies, Familial Idiopathic,Cardiomyopathies, Idiopathic Dilated,Congestive Cardiomyopathies,Dilated Cardiomyopathies,Dilated Cardiomyopathies, Idiopathic,Dilated Cardiomyopathy, Idiopathic,Familial Idiopathic Cardiomyopathies,Familial Idiopathic Cardiomyopathy,Idiopathic Cardiomyopathies, Familial,Idiopathic Cardiomyopathy, Familial,Idiopathic Dilated Cardiomyopathies,Idiopathic Dilated Cardiomyopathy
D005080 Exercise Test Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. Arm Ergometry Test,Bicycle Ergometry Test,Cardiopulmonary Exercise Testing,Exercise Testing,Step Test,Stress Test,Treadmill Test,Cardiopulmonary Exercise Test,EuroFit Tests,Eurofit Test Battery,European Fitness Testing Battery,Fitness Testing,Physical Fitness Testing,Arm Ergometry Tests,Bicycle Ergometry Tests,Cardiopulmonary Exercise Tests,Ergometry Test, Arm,Ergometry Test, Bicycle,Ergometry Tests, Arm,Ergometry Tests, Bicycle,EuroFit Test,Eurofit Test Batteries,Exercise Test, Cardiopulmonary,Exercise Testing, Cardiopulmonary,Exercise Tests,Exercise Tests, Cardiopulmonary,Fitness Testing, Physical,Fitness Testings,Step Tests,Stress Tests,Test Battery, Eurofit,Test, Arm Ergometry,Test, Bicycle Ergometry,Test, Cardiopulmonary Exercise,Test, EuroFit,Test, Exercise,Test, Step,Test, Stress,Test, Treadmill,Testing, Cardiopulmonary Exercise,Testing, Exercise,Testing, Fitness,Testing, Physical Fitness,Tests, Arm Ergometry,Tests, Bicycle Ergometry,Tests, Cardiopulmonary Exercise,Tests, EuroFit,Tests, Exercise,Tests, Step,Tests, Stress,Tests, Treadmill,Treadmill Tests
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.
April 1998, Lancet (London, England),
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial.
July 1996, Cardiovascular drugs and therapy,
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Long-term survival effect of metoprolol in dilated cardiomyopathy. The SPIC (Italian Multicentre Cardiomyopathy Study) Group.
April 1998, Heart (British Cardiac Society),
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.
June 1999, Journal of the American College of Cardiology,
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
[Dilated cardiomyopathy (idiopathic dilated cardiomyopathy)].
January 1996, Ryoikibetsu shokogun shirizu,
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy.
April 2002, The American journal of cardiology,
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Post-exercise Doppler-echocardiographic haemodynamics in idiopathic dilated cardiomyopathy after metoprolol infusion.
May 1994, Clinical science (London, England : 1979),
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy.
June 1999, Clinical cardiology,
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Metoprolol in patients with dilated cardiomyopathy.
June 1990, Circulation,
F Waagstein, and M R Bristow, and K Swedberg, and F Camerini, and M B Fowler, and M A Silver, and E M Gilbert, and M R Johnson, and F G Goss, and A Hjalmarson
Clinical and haemodynamic effects of oral metoprolol therapy in dilated cardiomyopathy.
January 1990, Indian heart journal,
Copied contents to your clipboard!